Sector News

Flannery wins top GE job after nursing growth at healthcare unit

June 13, 2017
Life sciences

When John Flannery was chosen to head GE Healthcare in 2014, his background as chief dealmaker for the industrial conglomerate led to speculation GE might consider spinning off its somewhat sickly health business.

In fact, he has nursed it back to improving sales and profits by focusing primarily on organic growth opportunities, and the business remains core to GE.

Flannery will take over General Electric Co from Jeff Immelt, who is stepping aside after 16 years as head of the conglomerate he helped steer through the financial crisis but which is now worth a third less than when he took over.

On Flannery’s watch, the healthcare unit – best-known for imaging and diagnostics – has also expanded into life sciences, offering a range of services to pharmaceutical and biotech companies.

GE faces tough competition for its medical imaging machines, which include MRI scanners and ultrasound devices, from rivals including Philips and Siemens, as well as younger Asian upstarts.

But a focus on expansion into new markets has helped lift sales at GE Healthcare to $18.3 billion last year, with organic revenue increasing by 5 percent and margins by 100 basis points.

Flannery has worked hard to move GE into newer areas of healthcare like life sciences, where GE has emerged as a significant player in helping with the production of biological drugs and cell therapies.

Such drugs, given by injection or infusion, are a pivotal driver of innovation in the drugs industry, being used to treat complex diseases from rheumatoid arthritis to cancer.

Flannery told Reuters last year he aimed to “double down on life sciences”, given this business’s large and high-margin opportunities.

One of the more innovative ideas launched by GE recently is the design of prefabricated drug factories for making complex biotech medicines, an idea it is pioneering in both China and Ireland.

GE reckons its “off-the-shelf” modular factories are 25 to 50 percent cheaper than the traditional plants and can be constructed in just 18 months rather than the typical three years.

Some analysts continue to question whether healthcare truly fits with mainstay GE industries like power generation and jet engines, but Flannery’s elevation suggests the group is not contemplating ditching healthcare any time soon.

In a sign of continuity, GE said Kieran Murphy, who currently heads life sciences, would lead the wider GE Healthcare division – and the company stated bluntly: “Healthcare is a key GE business now and in the future.”

By Ben Hirschler

Source: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.